IDH1 and central nervous system cancer: Over 80% of grades 2 and 3 gliomas carry IDH mutations, often IDH1 gain-of-function mutations, which prevent the formation of hydrogen bonds with the alpha and beta carboxyl sites in isocitrate and disrupt metabolic processes [31,32,33].